<DOC>
	<DOCNO>NCT01562015</DOCNO>
	<brief_summary>Phase 2 study subject ALK positive , advanced NSCLC fail 3 prior therapy . The study take place globally multiple study center . Subjects enrol receive ganetespib one time per week three week follow rest week ; repeat schedule cancer get bad subject unable tolerate ganetespib . The primary goal study determine ganetespib tolerate active ALK positive NSCLC .</brief_summary>
	<brief_title>A Study Ganetespib Subjects With ALK-Positive Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Males female age 18 year old Pathological confirmation advance NSCLC Evidence translocation inversion event involve ALK gene locus ECOG Performance Status 0 1 Prior therapy ALKtargeted agent Prior treatment Hsp90 inhibitor Known EGFR activate mutation Presence active untreated central nervous system ( CNS ) metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>